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Abstract
Background: Pediatric patients undergoing hematopoietic stem cell transplantation (HSCT) are at high risk of
acquiring fungal infections. Antifungal prophylaxis shortly after transplantation is therefore indicated, but data for
pediatric patients under 12 years of age are scarce. To address this issue, we retrospectively assessed the safety,
feasibility, and initial efficacy of prophylactic posaconazole in children.
Methods: 60 consecutive pediatric patients with a median age of 6.0 years who underwent allogeneic HSCT
between August 2007 and July 2010 received antifungal prophylaxis with posaconazole in the outpatient setting.
28 pediatric patients received an oral suspension at 5 mg/kg body weight b.i.d., and 32 pediatric patients received
the suspension at 4 mg/kg body weight t.i.d. The observation period lasted from start of treatment with
posaconazole until its termination (maximum of 200 days post-transplant).
Results: Pediatric patients who received posaconazole at 4 mg/kg body weight t.i.d. had a median trough level
of 383 μg/L. Patients who received posaconazole at 5 mg/kg body weight b.i.d. had a median trough level of
134 μg/L. Both regimens were well tolerated without severe side effects. In addition, no proven or probable
invasive mycosis was observed.
Conclusion: Posaconazole was a well-tolerated, safe, and effective oral antifungal prophylaxis in pediatric patients
who underwent high-dose chemotherapy and HSCT. Posaconazole at a dosage of 12 mg/kg body weight divided
in three doses produced consistently higher morning trough levels than in patients who received posaconazole
5 mg/kg body weight b.i.d. Larger prospective trials are needed to obtain reliable guidelines for antifungal
prophylaxis in children after HSCT.
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Background
Invasive fungal infection plays a major role in immuno-
compromised pediatric patients after high-dose chemother-
apy and allogeneic hematopoietic stem cell transplantation
(HSCT) [1-3]. Antifungal prophylaxis early after transplant-
ation is therefore indicated, yet data for oral antifungal
prophylaxis in pediatric patients who have undergone stem
cell transplantation are scarce. In our clinic, the intravenous
antifungal prophylaxis in pediatric HSCT recipients con-
sisted of liposomal amphotericin B (1 mg/kg/day) during
conditioning. On day +1 after HSCT we changed to caspo-
fungin in a dosage of 1 x 50 mg/m2/day due to lower
nephrotoxicity with comparable efficacy [4].
Posaconazole, a broad-spectrum triazole, has shown ac-
tivity against Candida spp., Aspergillus spp., Cryptococcus
spp., and certain agents of mucormycosis and fusariosis in
adults [5-8]. While most azole derivatives inhibit a broad
range of cytochrome c-dependent enzymes and interfere
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with other drugs, including immunosuppressants, posaco-
nazole is a potential inhibitor of CYP 3A4 and is not sig-
nificantly metabolized by any CYP isozyme [9-11].
Posaconazole was more effective than fluconazole or
itraconazole in prevention of invasive fungal infec-
tions in adult patients with myelodysplastic syndrome
or acute myeloid leukemia [12]. It was superior in
preventing invasive aspergillosis and reducing the
rate of deaths related to fungal infections in adults
with graft-versus-host disease [13]. A retrospective
analysis presented evidence that long-term posacona-
zole prophylaxis in adults after HSCT was associated
with few invasive mold infections [14].
The effectiveness and low incidence of side effects of
posaconazole in adults and break-through infections
with other azoles in our clinic was the rationale for
changing to posaconazole for oral prophylaxis in
pediatric patients. There was no drug licensed in Ger-
many for antifungal prophylaxis in children after BMT
at the time of this retrospective survey. To address
specific questions in relation to pharmacokinetic eva-
luations, we conducted plasma level measurements. In
this retrospective study, we analyzed the plasma con-
centrations of posaconazole during antifungal mono-
prophylaxis in two different posaconazole prophylaxis
regimens. We herein present the safety, feasibility, and
initial efficacy of antifungal prophylaxis with posacona-
zole after allogeneic HSCT in 60 pediatric patients
under 12 years of age.
Methods
Study design
In this retrospective, single-center study we analyzed
pediatric patients under 12 years of age who underwent
allogeneic HSCT from August 2007 to July 2010 at the
University Children’s Hospital Tübingen, Germany. This
retrospective study was performed under the waiver for
retrospective anonymized studies in accordance with the
institutional ethics regulations. Drug levels were ana-
lyzed in excessive blood samples drawn for routine la-
boratory tests. Posaconazole was commenced upon
discharge from the BMT unit following systemic anti-
fungal prophylaxis with liposomal amphotericin B or
caspofungin. We adapted the recommended dosage of
200 mg t.i.d. in adults (approximately equivalent to 10 -
12 mg/kg body weight in a adult weighing 50 - 60 kg) to
the weight of pediatric patients [9]. Patients received
posaconazole at either 5 mg/kg body weight b.i.d. or 4
mg/kg body weight t.i.d. Posaconazole was continued
until day 100 following allogeneic HSCT and then until
CD3+ T cells reached 200/μL and CD4+ T cells reached
100/μL in the peripheral blood as determined by flow
cytometry. The observation period in this retrospective
analysis was defined as the period from the start of
posaconazole until treatment cessation and was no
longer than day 200 after HSCT. The primary endpoint
of this trial was the incidence of proven or probable in-
vasive fungal infection during the observation period
under posaconazole therapy. Criteria for diagnosis of in-
vasive fungal infection were used as proposed by the Co-
operative Group of the European Organization for
Research and Treatment of Cancer and Mycoses Study
Group of the National Institute of Allergy and Infectious
Diseases (EORTC) [15]. Concerns about safety and toler-
ance provided secondary endpoints.
Assessment of safety and tolerance
Treatment-related clinical and laboratory adverse events
were registered, analyzed, and graded according to the
current US National Cancer Institute’s Common Ter-
minology Criteria for Adverse Events [16]. Blood ana-
lyses were recorded before, during, and at the end of
antifungal prophylaxis. Blood samples were taken at least
twice a week until day 100 and at least once a week
thereafter until day 200. Baseline values were analyzed
on the day before the start of posaconazole treatment.
Assessment of efficacy
During the course of treatment with posaconazole, all
pediatric patients were under continuous surveillance
for proven or probable fungal infections. Monitoring
took place via regular clinical assessment, routine la-
boratory analyses of factors including C-reactive protein
and galactomannan antigen, and computed tomography,
where indicated. At least once weekly until day 100
post-transplant, galactomannan antigen was measured
by an Aspergillus enzyme-linked immunosorbent assay
(PlateliaTM; Bio-Rad Laboratories, Munich, Germany).
Breakthrough infection was defined as proven and
probable invasive fungal infection according to
EORTC criteria of 2008 [15]. Successful oral antifun-
gal monoprophylaxis with posaconazole was defined
as the absence of fungal infection during and at the
end of oral prophylaxis as well as the absence of clin-
ical and laboratory adverse events associated with
posaconazole.
Posaconazole plasma concentrations
By examining the excess material remaining after labora-
tory analyses, which had been routinely cryopreserved,
we analyzed the trough plasma concentrations of posa-
conazole in six pediatric patients receiving posaconazole
at 5 mg/kg body weight b.i.d. and eight pediatric patients
receiving posaconazole at 4 mg/kg body weight t.i.d. by
high-performance liquid chromatography [17].
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Statistical considerations
All data were analyzed by descriptive and inferential sta-
tistics. The pharmacokinetic analysis, which compared
the measured posaconazole trough levels at the various
dosages, was performed via the Mann-Whitney U test.
The Wilcoxon matched-pairs signed-ranks test was used
for statistical comparison of continuous blood para-
meters, transaminases, and cholestasis parameters. To
determine whether our sample group exhibited statisti-
cally significantly different values from the age-adjusted
normal range, the one-sample t-test, taking into account
95% confident intervals, was used. Analysis of the influ-
ence of posaconazole on the CsA serum concentration
was first performed with the Friedman two-way analysis
of variance by ranks, then secondarily with the Wil-
coxon matched-pairs signed-ranks test, using four com-
parison points: days 2 to 3, days 4 to 6, days 8 to 12, and
days 16 to 20 after the start of posaconazole. P values
of ≤ 0.05 (*), ≤ 0.01 (**), and ≤ 0.001 (***) were defined
as statistically significant. Graphs were created with the
graphics program GraphPad Prism 4 for Windows, ver-
sion 4.03 (GraphPad Software, San Diego, CA, USA),
and statistical analysis was carried out with the statistical
program XLSTAT 2010 (Addinsoft, Paris, France).
Results
Patient characteristics
We assessed 60 consecutive pediatric patients (38 males,
22 females) under 12 years of age with hemato-
oncological malignancies and inborn errors of metabolism
who received primary oral antimycotic monoprophylaxis
with posaconazole after allogeneic HSCT. Posaconazole
was given in the outpatient setting and initiated two to
four days before discharge. The most common primary
diagnoses were acute lymphoblastic leukemia in 17
(28.3%) and aplastic anemia in 9 (15%) of 60 pediatric
patients. The median age was 6.0 years (range, 0.7 - 11.5
years). 30 of the 60 pediatric patients received a myeloa-
blative conditioning regimen (MAC), from which 12 of 30
received TBI, 2 of 30 were treated with busulfan, and 16
of 30 with treosulfan. 20 of the 60 pediatric patients
received a reduced-intensity conditioning regimen (RIC)
with melphalan. 5 patients received a conditioning regi-
men with fludarabin and thiotepa, 4 patients with fludara-
bin and cyclophosphamide, and 1 patient with thiotepa
and cyclophosphamide. Patients receiving a graft from a
MUD, MMUD or MFD received short course MTX and
CsA. Patients undergoing haploidentical transplantation
received a T-cell depleted graft and mycophenolate mofetil
only. All Patients with GvHD listed in Table 1 were
treated.
Twenty-eight pediatric patients received an oral sus-
pension of posaconazole at 5 mg/kg body weight b.i.d.,
and the remaining 32 patients received the suspension at
4 mg/kg body weight t.i.d. Not any other changes to the
allogeneic HSCT protocol or prophylaxis were made
simultaneously with the change in posaconazole dosing.
The median observation period for the treatment with
posaconazole lasted until day 162 after allogeneic HSCT
(with a range from day 24 to day 212 after HSCT). The
median treatment period with posaconazole was 127
days (range 12 - 188 days). Eight of the 60 pediatric
patients were monitored for a period less than one hun-
dred days after HSCT (with a range from 24 to 86 days
after HSCT). The intravenous antifungal prophylaxis
before the start of posaconazole was liposomal ampho-
tericin B in 23 patients and caspofungin in the remaining
37. Children received cotrimoxazole and aciclovir simul-
taneously with posaconazole.
The median duration of neutropenia pre-engraftment
was 12 days (range 10 - 24 days), mean 12.58 ± 1.84. Be-
cause of post-transplant complications in two patients
with intestinal graft-versus-host disease and two patients
with severe bacterial infection, oral posaconazole was
replaced by intravenous caspofungin. These patients
were included in the analysis until change of the antifun-
gal prophylaxis.
Efficacy analysis
All 60 pediatric patients were included in the final effi-
cacy analysis. There were no incidences of proven or
probable invasive fungal infection during treatment with
posaconazole as antifungal prophylaxis. Five patients
(8.3%) died of causes other than invasive fungal infec-
tion, including relapse of the underlying disease in four
cases, and a single case of disseminated intravascular
coagulation (DIC). Two of them died during the obser-
vation period with posaconazole. These patients were
included in the analysis until antifungal prophylaxis
with posaconazole was discontinued.
Safety and tolerability analysis
Side effects potentially related to posaconazole were
recorded in five (8.3%) of the 60 patients; these included
one patient with pruritus (1.7%), three with nausea (5%),
and one with vomiting (1.7%) (Table 2). All of these sec-
ondary effects were of severity grade I or II [16]. In the
cases of vomiting (n = 1) and nausea (n = 3), we ceased
the antifungal prophylaxis with posaconazole and con-
tinued with voriconazole, instead. These patients were
included in the analysis up until the last day of their
treatment with posaconazole.
Reconstitution of hematopoiesis, including platelets
and lymphocyte subpopulations, proceeded in a timely
manner (Figure 1). Hepatic function testing showed sig-
nificant grade I and II alanine aminotransferase (ALT)
elevations (P < 0.001) and grade I aspartate aminotrans-
ferase (AST) elevations (P < 0.001) during posaconazole
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treatment respective to baseline (Figure 2). In 84% of
patients, these increases emerged by day 14 after the
start of treatment. Interestingly, these parameters nor-
malized in 86% of patients by day 27 after the start of
posaconazole. The significant increases (P < 0.001) in
ALT and AST were observed in both treatment groups
(both b.i.d. and t.i.d. posaconazole therapy). Cholestasis
parameters, such as direct bilirubin, increased during
posaconazole treatment in two patients with grade II
elevations (one patient in each treatment group).
Cyclosporin A levels
Analysis of cyclosporin A (CsA) whole blood concentra-
tions was performed during the observation period in 28
pediatric patients treated with CsA + posaconazole. A
total of 16 (57.1%) pediatric patients exhibited a statisti-
cally significant yet moderate increase in CsA blood con-
centration (by 28%) on days 2 to 6 (P < 0.01) after the
start of posaconazole (Table 2), and a reduction in the
CsA dose, which ranged from 10% to 32%, was per-
formed in 12 (75.0%) of these 16 patients at that point.
Adjustments to the dosage of CsA after treatment day 8
took place in only one of the twelve (8.3%) patients. An
average CsA dose reduction of 22% (range, 10 - 32%)
was sufficient to compensate for these drug interactions.
Posaconazole levels
A total of 48 trough plasma concentrations of posacona-
zole were analyzed in 6 pediatric patients who had
Table 1 Patient characteristics





< 6 years 26 (43.3)







ALL relapse 11 (18.3)
AML 2 (3.3)
AML relapse 2 (3.3)




Solid tumors 7 (11.7)
Aplastic anemia 9 (15.0)
Neurometabolic diseases 4 (6.7)
Immunologic diseases 6 (10.0)
Chediak-Higashi-syndrome 1 (1.7)
Kostmann disease 1 (1.7)
Graft-versus-Host-Disease
Grade I 23 (38.3)
Grade II 3 (5.0)
Grade III 4 (6.7)
Grade IV 2 (3.3)
Chronic limited 2 (3.3)
Chronic extensive 1 (1.7)
Abbreviation: ALL, acute lymphoblastic leukemia; AML, acute myelogenous
leukemia; CML, chronic myeloid leukemia; JMML, juvenile myelomonocytic
leukemia; MDS, myelodysplastic syndromes, MFD, matched family donor;
MMFD, mismatched family donor; MUD, matched unrelated donor.
Table 2 Clinical and laboratory adverse events of
antifungal prophylaxis
Variable No. (%) (n = 60)
Drug related adverse events





Increase in alanine aminotransferase
≥ 2.0 x normal value 39 U/L 10 (16.7)
≥ 3.0 x normal value 39 U/L 9 (15)
Increase in aspartate aminotransferase
≥ 2.0 x normal value 59 U/L 1 (1.7)
≥ 3.0 x normal value 59 U/L 0 (0)
Increase in total bilirubin
≥ 2.0 x normal value 1.1 mg/dl 0 (0)
≥ 3.0 x normal value 1.1 mg/dl 0 (0)
Increase in direct bilirubin
≥ 2.0 x normal value 0.3 mg/dl 2 (3.4)
≥ 3.0 x normal value 0.3 mg/dl 0 (0)
Analysis of cyclosporin A level (n = 28)
≥ 1.5 x baseline day 2-3 8 (28.6)
≥ 2.0 x baseline day 2-3 2 (7.1)
≥ 1.5 x baseline day 4-6 9 (32.1)
≥ 2.0 x baseline day 4-6 1 (3.6)
≥ 1.5 x baseline day 8-12 4 (14.3)
≥ 2.0 x baseline day 8-12 1 (3.6)
≥1.5 x baseline day 16-20 1 (3.6)
≥ 2.0 x baseline day 16-20 0 (0.0)
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Figure 1 Blood analyses. Box plot of peripheral blood cell count values the day before posaconazole therapy began (Begin) and at the end of
oral antimycotic monoprophylaxis with posaconazole (End). A: Platelet counts. B: CD3+ cell counts. C: CD4+ cell counts. D: CD16+/CD56+ cell
counts. A timely reconstitution of platelets (***P < 0.001), CD3+ cell counts, and CD4+ cell counts took place during posaconazole treatment.
Figure 2 Hepatotoxicity. Box plot of liver parameters the day before posaconazole therapy began (Before), their maximums during therapy
(Maximum), and values at the end of oral antimycotic monoprophylaxis with posaconazole (End). A: Plasma alanine aminotransferase (ALT)
(normal value, ≤ 39 U/L). B: Plasma aspartate aminotransferase (AST) (normal value, ≤ 59 U/L for pediatric patients < 12 years of age). C: Total
plasma bilirubin (normal value, ≤ 1.1 mg/dL). D: Direct plasma bilirubin (normal value, ≤ 0.3 mg/dL). Statistical analysis by the Wilcoxon
matched-pairs signed-ranks test showed a significant increase (***P < 0.001) in ALT and AST beyond their upper normal limits during treatment
post-transplant respective to baseline measurements taken the day before the start of posaconazole prophylaxis (Before).
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received an oral suspension of posaconazole at 5 mg/kg
body weight b.i.d., and a total of 41 trough plasma con-
centrations of posaconazole were analyzed in 8 pediatric
patients who had received an oral suspension of posaco-
nazole at 4 mg/kg body weight t.i.d. Demographic char-
acteristics of these 14 pediatric patients are presented in
Table 3. Pediatric patients who received posaconazole
t.i.d. had consistently higher morning trough levels (me-
dian, 383 μg/L; range, 61 - 1243 μg/L; mean, 434.81 ±
241.01 μg/L) in the observation period from day 3 to 164
after starting posaconazole compared with patients who
received posaconazole b.i.d. (median, 134 μg/L; range,
56 - 786 μg/dl; mean, 221.4 ± 188.8 μg/L) in the observa-
tion period from day 3 to 184 after the start of treatment.
These morning trough levels were significantly different
(P < 0.001) according to the Mann-Whitney U test
(Figure 3). There were no significant differences in the
trough plasma concentrations of posaconazole between
patients < 6 years of age and patients 6 to 11 years of
age, who had received posaconazole at 5 mg/kg body
weight b.i.d. (P = 0.36) and patients who had received
posaconazole at 4 mg/kg body weight t.i.d. (P = 0.77).
In terms of food intake, the mean posaconazole trough
level (n = 28) was 33.5% to 63.5% higher in children
who received posaconazole during a fatty meal (e.g., a
meal including a spoon of coffee cream and posacona-
zole) compared with the mean trough level in children
who received posaconazole with a meal without coffee
cream or, in some cases, without any food at all. The
trough levels (n = 13) in the two patients who
received posaconazole b.i.d. with a fatty meal (median,
330 μg/L; mean, 319.6 ± 187.13 μg/L) were significant
higher (P = 0.025) than the trough levels (n = 35) in
four patients who received posaconazole b.i.d. with a
normal meal without coffee cream or without any food
at all (median, 133 μg/L; mean, 199.63 ± 181.08 μg/L).
In three patients who received posaconazole t.i.d. with
a fatty meal, the posaconazole trough levels (n = 15)
(median, 467 μg/L; mean, 450 ± 129.71 μg/L) were
higher than the trough levels (n = 26) in five patients
who received posaconazole with a normal meal (median,
361 μg/L; mean, 337 ± 127.25 μg/L), but the difference
was not significant (P = 0.09). The first measured posaco-
nazole trough levels early after the start of posaconazole
treatment between days 3 and 6 were lower in both treat-
ment regimen groups. The mean posaconazole trough
level increased significantly (P = 0.049) between days 3
and 6 (median, 91 μg/L; mean, 112.71 ± 91.42 μg/L) and
after day 7 (median, 136 μg/L; mean, 230.6 ± 197.37 μg/L)
in patients who received posaconazole b.i.d. Patients who
received posaconazole t.i.d. showed lower trough levels
between days 3 and 6 (mean, 302.25 ± 183.67 μg/L; me-
dian, 330 μg/L; range, 61 - 488 μg/L) than those after day
7 (mean, 476.21 ± 246.87 μg/L; median, 404 μg/L; range,
291 - 1243 μg/L), but the difference was not significant
(P = 0.27). Seventy-nine (88.7%) of all (n = 89) posaco-
nazole trough levels in this retrospective analysis were
measured during the use of H2 receptor antagonist ra-
nitidine or the proton pump inhibitor omeprazole.
Three of 24 pediatric patients in whom posaconazole
trough levels were measured experienced diarrhea.
These cases consisted of two of the children who had
received posaconazole three times daily and one child
who had received posaconazole twice daily. In none of
these children did the levels lay lower than the trough
levels of the children in the same group without
diarrhea.
Discussion
No drugs were licensed in Germany for use as antifungal
prophylaxis in children after BMT at the time when this
Table 3 Characteristics of patients with posaconazole
level monitoring
Characteristic Posaconazole administration
2 x per day (n = 6) 3 x per day (n = 8)
No. of patients (%)
Gender
Male 2 (33.3) 5 (62.5)
Female 4 (66.6) 3 (37.5)
Age group
< 6 years 3 (5.0) 6 (75.0)
6-11 years 3 (5.0) 2 (25.0)
Donor
MUD 2 (33.3) 3 (37.5)
MMFD 2 (33.3) 5 (62.2)
MFD 2 (33.3) 0 (0)
Primary diagnosis
ALL 1 (16.7) 2 (25.0)
Biphenotypic leukemia 0 (0) 1 (12.5)
Solid tumors 1 (16.7) 0 (0)
Aplastic anemia 2 (33.3) 1 (12.5)
Neurometabolic diseases 1 (16.7) 1 (12.5)
Immunodeficiency 1 (16.7) 3 (37.5)
Graft-versus-Host disease
Grade I 2 (33.3) 2 (25.0)
Grade II 0 (0) 2 (25.0)
Grade III 0 (0) 0 (0)
Grade IV 0 (0) 0 (0)
Chronic limited 0 (0) 0 (0)
Chronic extensive 0 (0) 0 (0)
Abbreviation: ALL, indicates acute lymphoblastic leukemia; MFD, matched
family donor; MMFD, mismatched family donor; MUD, matched unrelated
donor.
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retrospective survey took place. Furthermore, we had
observed breakthrough infections with the treatment of
azoles other than posaconazole in the past. In a histor-
ical group of 50 pediatric patients whom we had treated
in our center with an antifungal prophylaxis with itraco-
nazole after allogeneic HSCT, three possible fungal
infections were observed. This data is in concordance
with data obtained at other centers [18]. These reasons
prompted our choice of posaconazole, due to its promis-
ing results in adult patients. To address specific ques-
tions with regard to pharmacokinetic evaluations, we
conducted plasma level measurements. According to the
current guidelines for antifungal management in adult
patients, posaconazole is recommended as primary anti-
fungal prophylaxis following allogeneic HSCT [19].
Based on the data on posaconazole as oral antifungal
prophylaxis in adults we decided to use posaconazole in
pediatric patients as well [12,13].
We retrospectively assessed data on the plasma levels,
efficacy, safety, and tolerability of posaconazole in 60
pediatric patients under 12 years of age after HSCT.
Varying dosages of posaconazole as antifungal prophy-
laxis and therapy for invasive fungal infections have been
reported in adults [5,12], while dosages for pediatric
patients have not yet been defined [20,21]. We adapted
the recommended prophylactic dosage of 600 mg/day in
adults to the weight of pediatric patients [9]. Initially,
the frequency of administration of posaconazole was 5
mg/kg b.i.d. However, data became available showing
that trough levels of pediatric patients were lower and
less stable compared with those reported in adults
[12,13,22,23]. Therefore, the frequency of administration
and daily dosage were increased to 4 mg/kg t.i.d.
Posaconazole trough levels under the latter regimen
were consistently higher than trough levels in patients
who received posaconazole b.i.d. and only slightly lower
than posaconazole trough levels in adults undergoing
posaconazole prophylaxis [12,13]. In another report posa-
conazole levels > 0.5 mg/L correlated with a better out-
come [24]. Although we mostly found lower values in our
patient cohort, no invasive fungal infections were
observed. This illustrates that a prospective randomized
controlled study in pediatric patients is of pressing im-
portance to verify this data. There is only one published
pediatric study on dose determination involving a small
group of 12 pediatric and juvenile patients (median age,
15 years) with invasive fungal infections; the therapeutic
dose of posaconazole in 11 of 12 patients was 800 mg/day
in divided doses with a median posaconazole through
level of 579 ng/mL (range, 85.3 - 2891 ng/mL; mean,
776 ng/mL) [25]. In our prophylaxis study, we observed
lower posaconazole trough levels (median, 404 ng/mL;
range, 291 - 1243 ng/mL; mean, 476 ± 246.84 ng/mL)
from day 7 after the start of treatment at 4 mg/kg t.i.d.
A randomized crossover study with healthy subjects
showed the highest posaconazole levels during and after
a high-fat meal and with avoidance of proton pump inhi-
bitors [26]. Most of the pediatric patients enrolled in our
retrospective analysis received a proton pump inhibitor
(76.67%, n = 46) or a H2 receptor antagonist (10%, n = 6)
at least once a day during analysis of posaconazole
trough levels; it is probable that the trough levels would
be higher with avoidance of proton pump inhibitors.
Only a few studies have been published on the usage of
posaconazole in pediatric patients with a small number
of cases. A multi-center retrospective survey reported
data on 15 pediatric patients (median age, 10 years) with
invasive fungal infections, most of them with hemato-
oncological malignancies, who received posaconazole sal-
vage therapy at a median dosage of 21 mg/kg body
weight (range, 4.8 - 33.3 mg/kg). Posaconazole was ef-
fective as salvage therapy for proven and probable inva-
sive fungal infections [20]. Another retrospective survey
on the off-label use of posaconazole as secondary
prophylaxis and rescue therapy included 15 pediatric
patients (median age, 10 years). Twelve of these patients
experienced an invasive fungal infection, i.e. proven as-
pergillosis in one patient, probable aspergillosis in ten
patients and possible mycosis in one patient. Three
patients received posaconazole as primary (n = 2), and
secondary (n = 1) prophylaxis in high-risk situations, i. e.
treatment with steroids, acute GvHD, and haploidentical
HSCT. 9 of the 15 patients were post-HSCT. Patients
received varying dosages, including 200 mg/day (t.i.d.) in
12 cases, 400 mg/day (b.i.d.) in two cases, and 100 mg/day
(t.i.d.) in a single patient [21]. Posaconazole was well
tolerated and showed significant clinico-radiological
Figure 3 Posaconazole trough levels. Analysis of posaconazole
morning trough levels at 5 mg/kg body weight daily (b.i.d.) (n = 48)
and morning trough levels at 4 mg/kg body weight daily (t.i.d.)
(n = 41). These morning trough levels were significantly different
(P < 0.001) according to the Mann-Whitney U test. The gray area
indicates the reported range of posaconazole trough levels in adults.
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improvements in 9 of these 12 patients. In our pediatric
patients, we observed a significant but moderate and re-
versible increase in the liver parameters ALT and AST.
This finding corresponds with observations made in
a retrospective study of salvage therapy in pediatric
patients [20]. The survey also reported side effects simi-
lar to those in our analysis, such as nausea and vomiting.
Drug interactions involving posaconazole and calcineurin
inhibitors can occur due to inhibition of the CYP3A4 iso-
enzyme [11]. We observed a significant increase in the
CsA plasma concentration in 16 (57.1%) of the 28 pediatric
patients in our cohort. An average CsA dose reduction of
22% (range, 10 - 32%) was sufficient to adjust for this re-
action. Similar elevated CsA trough levels were also
observed in up to 41% of patients in another retrospect-
ive review of adult and pediatric HSCT recipients after
voriconazole administration [27]. The limitations of the
measured posaconazole levels in our analysis are that
they took place retrospectively from excess material
remaining after laboratory analyses which had been rou-
tinely cryopreserved, and that only on arbitrary time
points after day seven (the point commonly known to be
the time when a steady state of posaconazole levels
plasma is reached) were possible. It is of utmost import-
ance to establish a pharmacokinetic analysis within
the framework of a prospective, randomized study in
pediatric patients.
Conclusions
We retrospectively studied posaconazole as oral antifun-
gal prophylaxis in the largest published cohort of post-
HSCT pediatric patients under 12 years of age to date.
We conclude that posaconazole at a dosage of 4 mg/kg
body weight t.i.d. with a fatty meal is an effective, safe,
and well-tolerated antifungal prophylactic regimen in
these pediatric patients. We observed a low incidence of
side effects and continually stable posaconazole serum
concentrations. Because of our favorable experience with
posaconazole as antifungal prophylaxis in pediatric
patients after allogeneic HSCT, we are currently using
this regimen at a dosage of 4 mg/kg body weight t.i.d.
Prospective clinical trials in pediatric patients are needed
to compare posaconazole with other antifungals and
identify drug interactions in this cohort.
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